Dr. Daniel Tang has been named general manager, Asia Pacific for ICON plc's Development Solutions business. Dr. Tang will lead the development of ICON’s early phase activities across the region, including bioanalytical laboratory services, and the development of strong links with Key Opinion Leaders for early phase clinical testing.
 
Dr. Tang has more than 15 years’ experience in drug research, especially in regulated bioanalysis. Prior to joining ICON, he was vice president of Operations and Bioassay/DMPK of Frontage Laboratories. Previously, he served as vice president DMPK at ChemPartner, where he established a bioanalytical facility in Shanghai, China. Dr. Tang also held senior scientific positions with QPS and Pfizer in the U.S., before returning to China in 2007.
 
Dr. Mario Rocci, president, ICON Development Solutions, said, “We are very pleased to welcome Dr. Tang to ICON. His expertise, experience and leadership will be critical as we expand our presence and range of services in the Asia Pacific region to support the growing clinical trials market there.”  
 
Dr. Tang is an expert in regulated bioanalysis and has authored numerous research papers, conference abstracts and invited presentations, including a contribution to the 2009 industry white paper on Incurred Sample Re-analysis, which later helped form industry best practices. Dr. Tang has also helped establish the first bioanalytical discussion group in Shanghai and is currently leading efforts to increase the GLP awareness and compliance of bioanalysis in the Chinese bioanalytical community. He is a steering committee member of the Global Bioanalysis Consortium, representing the Asia Pacific region.